A STUDY TO COMPARE THE WEIGHT, BLOOD SUGAR AND FAT CHANGES IN PATIENTS ON TREATMENT WITH OLANZAPINE, RISPERIDONE AND QUETIAPINE.
- Conditions
- Health Condition 1: F01-F99- Mental, Behavioral and Neurodevelopmental disorders
- Registration Number
- CTRI/2019/05/019447
- Lead Sponsor
- Father Muller Medical College Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Patients taking antipsychotic treatment with any one of the drugs: Olanzapine, Risperidone, Quetiapine, for a minimum period of 6 months to a maximum period of 1 year.
Not on monotherapy with study drugs
Patient is a known case of diabetes or dyslipidemia or has a Pretreatment history of diabetes or dyslipidemia.
Patients on Lithium, Nortriptyline, Amitriptyline, valproic acid, antidepressants for past 3 months and other psychotropic agents known to affect insulin sensitivity.
Those on other non-psychiatric drugs known to cause weight gain, hyperglycemia or dyslipidemia like steroids, diuretics, hyperglycemia producing antiepileptics.
Have current substance abuse or dependency disorder.Pregnancy.
Any clinically relevant disease (liver, renal or heart disease).
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method